C

China Resources Pharmaceutical Group Ltd
HKEX:3320

Watchlist Manager
China Resources Pharmaceutical Group Ltd
HKEX:3320
Watchlist
Price: 5.57 HKD 1.27% Market Closed
Market Cap: 35B HKD
Have any thoughts about
China Resources Pharmaceutical Group Ltd?
Write Note

China Resources Pharmaceutical Group Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Pharmaceutical Group Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Total Equity
HK$48.4B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Total Equity
HK$15.7B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
33%
U
United Laboratories International Holdings Ltd
HKEX:3933
Total Equity
ÂĄ13.5B
CAGR 3-Years
14%
CAGR 5-Years
16%
CAGR 10-Years
9%
Sino Biopharmaceutical Ltd
HKEX:1177
Total Equity
ÂĄ32.8B
CAGR 3-Years
10%
CAGR 5-Years
2%
CAGR 10-Years
22%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Total Equity
ÂĄ21.4B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
22%
H
HUTCHMED (China) Ltd
HKEX:13
Total Equity
$740.1m
CAGR 3-Years
-9%
CAGR 5-Years
16%
CAGR 10-Years
23%
No Stocks Found

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
35B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
16.42 HKD
Undervaluation 66%
Intrinsic Value
Price
C

See Also

What is China Resources Pharmaceutical Group Ltd's Total Equity?
Total Equity
48.4B HKD

Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Total Equity amounts to 48.4B HKD.

What is China Resources Pharmaceutical Group Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
3%

Over the last year, the Total Equity growth was 6%.

Back to Top